RSS-Feed abonnieren
DOI: 10.1055/s-2004-815608
Diffuse Panbronchiolitis
Publikationsverlauf
Publikationsdatum:
15. Januar 2004 (online)
![](https://www.thieme-connect.de/media/srccm/200305/lookinside/thumbnails/10.1055-s-2004-815608-1.jpg)
ABSTRACT
Diffuse panbronchiolitis (DPB) was first distinguished from chronic obstructive pulmonary diseases in the early 1960s and recorded as a new clinicopathologic entity. This disease affects East Asians for the major part, and is characterized by chronic sinobronchial infection together with diffuse bilateral micronodular pulmonary lesions consisting of inflammatory cells. The prognosis at an advanced stage would often be bleak, where superinfection with Pseudomonas aeruginosa had occurred. Beginning with an initial success of erythromycin therapy, considerable improvement has been achieved in the prognosis of this disease. Simple bactericidal activity of macrolides is not a determinant factor for the clinical effect. An in-depth study, together with its pathogenesis, has been performed to clarify the underlying mechanism. Inhibitions of excessive mucus and water secretion from airway epithelium, neutrophil accumulation in the large airway, lymphocyte and macrophage accumulation around the small airway, and modulation of bacterial virulence have so far been proposed as possible mechanisms.
KEYWORDS
Macrolides - chronic airway infection
REFERENCES
- 1 Honma H. Diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1975; 13 383-395
- 2 Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis [in Japanese]. Naika . 1969; 23 442-451
- 3 Izumi T, Doi O, Nobechi A. et al .Nation-wide survey of diffuse panbronchiolitis [author's transl] [in Japanese]. Annual Report on the study of interstitial lung disease in 1982. Tokyo:.Grant-in Aid from the Ministry of Health and Welfare of Japan; 1983: 3-41
- 4 Homma H, Yamanaka A, Tanimoto S. et al . Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest . 1983; 83 63-69
- 5 Kudoh S, Uetake T, Hagiwara K. et al . Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1987; 25 632-642
- 6 Homma H. Diffuse panbronchiolitis. Jpn J Med . 1986; 25 329-334
- 7 Kim Y W, Han S K, Shim Y S. et al . The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med . 1992; 31 695-701
- 8 Chu Y C, Yeh S Z, Chen C L, Chen C Y, Chang C Y, Chiang C D. Diffuse panbronchiolitis: report of a case. J Formos Med Assoc . 1992; 91 912-915
- 9 Tredaniel J, Cazals-Hatem D, Zalcman G, d'Agay M F, Capron F. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med . 1994; 88 479-480
- 10 Homer R J, Khoo L, Smith G J. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest . 1995; 107 1176-1178
- 11 Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chin Med J (Engl) . 1996; 109 949-952
- 12 Zainudin B M, Roslina A M, Fadilah S A, Samad S A, Sufarlan A W, Isa M R. A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med J Malaysia . 1996; 51 136-140
- 13 Wang H, Sun T, Miao J, Li Y. A definite case of diffuse panbronchiolitis diagnosed by open lung biopsy. Chin Med J (Engl) . 1998; 111 864
- 14 Tsang K W, Ooi C G, Ip M S. et al . Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax . 1998; 53 274-280
- 15 Poh S C, Wang Y T, Wang W Y. Diffuse panbronchiolitis: a case report. Singapore Med J . 2001; 42 271-274
- 16 Randhawa P, Hoagland M H, Yousem S A. Diffuse panbronchiolitis in North America: report of three cases and of the literature. Am J Surg Pathol . 1991; 15 43-47
- 17 Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male. Sarcoidosis . 1992; 9 67-69
- 18 Fitzgerald J E, King Jr E T, Lynch D A, Tuder R M, Schwarz M I. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med . 1996; 154(2 Pt 1) 497-503
- 19 Schulte W, Szrepka A, Bauer P C, Guzman J, Costabel U. Diffuse panbronchiolitis: a rare differential diagnosis of chronic obstructive lung disease [in German]. Dtsch Med Wochenschr . 1999; 124 584-588
- 20 Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand. J Med Assoc Thai . 1999; 82 833-838
- 21 Gulhan M, Erturk A, Kurt B. et al . Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc Diffuse Lung Dis . 2000; 17 292-296
- 22 Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust N Z J Med . 2000; 30 99-100
- 23 Martinez J A, Guimaraes S M, Ferreira R G, Pereira C A. Diffuse panbronchiolitis in Latin America. Am J Med Sci . 2000; 319 183-185
- 24 Fisher Jr S M, Rush W L, Rosado-de-Christenson M L. et al . Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med . 1998; 122 156-160
- 25 Brugiere O, Milleron B, Antoine M, Carette M F, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax . 1996; 51 1065-1067
- 26 Corne J. Diffuse panbronchiolitis: a new Japanese export?. Lancet . 1996; 348 1465-1466
- 27 Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1990; 141 1459-1462
- 28 Keicho N, Tokunaga K, Nakata K. et al . Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med . 1998; 158 846-850
- 29 Park M H, Kim Y W, Yoon H I. et al . Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med . 1999; 159 526-529
- 30 Keicho N, Ohashi J, Tamiya G. et al . Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet . 2000; 66 501-507
- 31 Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax . 1994; 49 531-532
- 32 Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis . 1992; 146 781-783
- 33 Ichikawa Y, Ninomiya H, Koga H. et al . Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis . 1992; 146 196-203
- 34 Kadota J, Sakito O, Kohno S. et al . A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1993; 147 153-159
- 35 Yoshimura K, Iizuka S, Anzai C. et al . Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am J Respir Crit Care Med . 2000; 161 A77
- 36 Sugiyama Y, Kudoh S, Kitamura S. A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1989; 27 980-983
- 37 Donato L, de la Salle H, Hanau D. et al . Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr . 1995; 127 895-900
- 38 Teisserenc H, Schmitt W, Blake N. et al . A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett . 1997; 57 183-187
- 39 Furukawa H, Murata S, Yabe T. et al . Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest . 1999; 103 755-758
- 40 Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest . 1999; 103 595-596
- 41 Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis . 2001; 18 312-313
- 42 Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn . 1987; 37 693-704
- 43 Iwata M, Colby T V, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol . 1994; 25 357-363
- 44 Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1992; 146 473-478
- 45 Mukae H, Kadota J, Kohno S. et al . Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med . 1995; 152 613-618
- 46 Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest . 1990; 98 917-923
- 47 Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest . 1994; 106 1116-1123
- 48 Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest . 1995; 108 116-122
- 49 Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration . 1996; 63 42-48
- 50 Oishi K, Sonoda F, Kobayashi S. et al . Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun . 1994; 62 4145-4152
- 51 Kusano S, Kadota J, Kohno S. et al . Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration . 1995; 62 217-222
- 52 Beringer P M. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med . 1999; 5 371-377
- 53 Konstan M W. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med . 1998; 19 505-513
- 54 Akira M, Kitatani F, Lee Y S. et al . Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology . 1988; 168 433-438
- 55 Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology . 1992; 184 779-785
- 56 Hansell D M. Small airways diseases: detection and insights with computed tomography. Eur Respir J . 2001; 17 1294-1313
- 57 Takizawa H, Tadokoro K, Miyoshi Y. et al . Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1986; 24 257-263
- 58 Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax . 1994; 49 540-544
- 59 Nakata K. Revision of clinical guidelines for DPB [author's transl] [in Japanese]. Annual Report on the study of diffuse lung disease in 1998. Tokyo:Grant-in Aid from the Ministry of Health and Welfare of Japan; 1999: 109-111
- 60 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-first report: comparison with amoxicillin [in Japanese]. Kansenshogaku Zasshi . 1986; 60 37-44
- 61 Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1990; 28 1305-1313
- 62 Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration . 1991; 58 145-149
- 63 Fujii T, Kadota J, Kawakami K. et al . Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax . 1995; 50 1246-1252
- 64 Yamada G, Igarashi T, Itoh E, Tanaka H, Sekine K, Abe S. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest . 2001; 120 198-202
- 65 Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis: detection by high-resolution computed tomography. Chest . 1995; 107 120-125
- 66 Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology . 1993; 189 559-562
- 67 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections [in Japanese]. Kansenshogaku Zasshi . 1986; 60 45-50
- 68 Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1990 [in Japanese] Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan 1991: 18-20
- 69 Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med . 1998; 157(6 Pt 1) 1829-1832
- 70 Nakamura H, Fujishima S, Inoue T. et al . Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J . 1999; 13 1371-1379
- 71 Mikasa K, Sawaki M, Kita E. et al . Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases-the fourth report [in Japanese]. Kansenshogaku Zasshi . 1992; 66 1097-10104
- 72 Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother . 1995; 39 1688-1690
- 73 Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med . 1995; 34 469-474
- 74 Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1999. Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan; 2000: 111
- 75 Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med . 1998; 4 116-121
- 76 Koyama H, Geddes D M. Erythromycin and diffuse panbronchiolitis. Thorax . 1997; 52 915-918
- 77 Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol . 2001; 31 464-473
- 78 Rubin B K, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs . 2000; 1 169-172
- 79 Kadota J. Antiinflammatory effects of macrolide therapy in patients with diffuse panbronchiolitis, a chronic inflammatory airway disease. Recent Res Devel Antimicrob Agents & Chemother . 1999; 3(Pt 1) 17-38
- 80 Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax . 1999; 54 (suppl 2) S58-S62
- 81 Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents . 2001; 18 (suppl 1) S83-S87
- 82 Labro M T. Anti-inflammatory activity of macrolides: a new therapeutic potential?. J Antimicrob Chemother . 1998; 41 (suppl B) S37-S46
- 83 Hoyt J C, Robbins R A. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett . 2001; 205 1-7
- 84 Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol . 2001; 429 209-229
- 85 Azuma A. Novel activity of erythromycin derivatives on inflammatory lung diseases. Recent Res Devel Respir Crit Care Med . 2001; 1 191-207
- 86 Rubin B K, Druce H, Ramirez O E, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med . 1997; 155 2018-2123
- 87 Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J . 1992; 5 234-238
- 88 Kondo M, Kanoh S, Tamaoki J, Shirakawa H, Miyazaki S, Nagai A. Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells. Am J Respir Cell Mol Biol . 1998; 19 799-804
- 89 Zhao D M, Xue H H, Chida K. et al . Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol . 2000; 278 L726-736
- 90 Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S. Erythromycin does not directly affect neutrophil functions. Chest . 1994; 105 520-523
- 91 Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol . 1997; 114 111-115
- 92 Takizawa H, Desaki M, Ohtoshi T. et al . Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med . 1997; 156 266-271
- 93 Desaki M, Takizawa H, Ohtoshi T. et al . Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun . 2000; 267 124-128
- 94 Aoki Y, Kao P N. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother . 1999; 43 2678-2684
- 95 Abe S, Nakamura H, Inoue S. et al . Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol . 2000; 22 51-60
- 96 Khair O A, Devalia J L, Abdelaziz M M, Sapsford R J, Davies R J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J . 1995; 8 1451-1457
- 97 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) . 1993; 46 1406-1413
- 98 Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother . 1994; 38 2643-2647
- 99 Kita E, Sawaki M, Nishikawa F. et al . Enhanced interleukin production after long-term administration of erythromycin stearate. Pharmacology . 1990; 41 177-183
- 100 Sugiyama Y, Yanagisawa K, Tominaga S I, Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J . 1999; 14 1113-1116
- 101 Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol . 1999; 163 2909-2915
- 102 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo) . 1994; 47 80-89
- 103 Howe R A, Spencer R C. Macrolides for the treatment of Pseudomonas aeruginosa infections?. J Antimicrob Chemother . 1997; 40 153-155
- 104 Kita E, Sawaki M, Oku D. et al . Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother . 1991; 27 273-284
- 105 Sakata K, Yajima H, Tanaka K. et al . Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis . 1993; 148(4 Pt 1) 1061-1065
- 106 Molinari G, Guzman C A, Pesce A, Schito G C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother . 1993; 31 681-688
- 107 Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med . 1995; 99(6A) 26S-30S
- 108 Davies D G, Parsek M R, Pearson J P, Iglewski B H, Costerton J W, Greenberg E P. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science . 1998; 280 295-298
- 109 Tateda K, Comte R, Pechere J C, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother . 2001; 45 1930-1933